Mangrove Partners’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Mangrove Partners’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-31,990	Closed	-$313K	–	584
2021 Q3	$313K	Sell	31,990 -1,100	-3%	-$10.7K	0.03%	339
2021 Q2	$326K	Buy	+33,090	New	+$326K	0.03%	279

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Mangrove Partners's EUCR Position: Q4 2021 in Review

Mangrove Partners sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2021, closing a stake of 31,990 shares — an estimated $313K sold.

Mangrove Partners first reported a position in EUCR in Q2 2021 and held it in 2 quarters. The position peaked at $326K in Q2 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q4 2021.

Mangrove Partners reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2021 after selling out during the quarter.
Mangrove Partners sold 31,990 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2021, an estimated $313K.
Mangrove Partners first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 2 quarters.
Mangrove Partners's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $326K in Q2 2021.
39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2021.

Based on Mangrove Partners's 13F filing for Q4 2021, filed 14 Feb 2022.